Testing effectiveness (Phase 2)Looking for participantsNCT06051695
What this trial is testing
Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Who this might be right for
Solid Tumor, AdultColorectal CancerNSCLC+17 more
A2 Biotherapeutics Inc. 474